Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing, China.
J Nanobiotechnology. 2024 Jul 18;22(1):423. doi: 10.1186/s12951-024-02711-1.
Rheumatoid arthritis (RA) is a chronic autoimmune disease marked by synovitis and cartilage destruction. The active compound, icariin (ICA), derived from the herb Epimedium, exhibits potent anti-inflammatory properties. However, its clinical utility is limited by its water insolubility, poor permeability, and low bioavailability. To address these challenges, we developed a multifunctional drug delivery system-adipose-derived stem cells-exosomes (ADSCs-EXO)-ICA to target active macrophages in synovial tissue and modulate macrophage polarization from M1 to M2. High-performance liquid chromatography analysis confirmed a 92.4 ± 0.008% loading efficiency for ADSCs-EXO-ICA. In vitro studies utilizing cellular immunofluorescence (IF) and flow cytometry demonstrated significant inhibition of M1 macrophage proliferation by ADSCs-EXO-ICA. Enzyme-linked immunosorbent assay, cellular transcriptomics, and real-time quantitative PCR indicated that ADSCs-EXO-ICA promotes an M1-to-M2 phenotypic transition by reducing glycolysis through the inhibition of the ERK/HIF-1α/GLUT1 pathway. In vivo, ADSCs-EXO-ICA effectively accumulated in the joints. Pharmacodynamic assessments revealed that ADSCs-EXO-ICA decreased cytokine levels and mitigated arthritis symptoms in collagen-induced arthritis (CIA) rats. Histological analysis and micro computed tomography confirmed that ADSCs-EXO-ICA markedly ameliorated synovitis and preserved cartilage. Further in vivo studies indicated that ADSCs-EXO-ICA suppresses arthritis by promoting an M1-to-M2 switch and suppressing glycolysis. Western blotting supported the therapeutic efficacy of ADSCs-EXO-ICA in RA, confirming its role in modulating macrophage function through energy metabolism regulation. Thus, this study not only introduces a drug delivery system that significantly enhances the anti-RA efficacy of ADSCs-EXO-ICA but also elucidates its mechanism of action in macrophage function inhibition.
类风湿关节炎(RA)是一种慢性自身免疫性疾病,其特征为滑膜炎和软骨破坏。从淫羊藿属植物中提取的活性化合物淫羊藿苷(ICA)具有很强的抗炎作用。然而,其临床应用受到水溶性差、通透性差和生物利用度低的限制。为了解决这些挑战,我们开发了一种多功能药物递送系统-脂肪来源干细胞-外泌体(ADSCs-EXO)-ICA,以靶向滑膜组织中的活性巨噬细胞,并调节巨噬细胞从 M1 向 M2 极化。高效液相色谱分析证实 ADSCs-EXO-ICA 的载药效率为 92.4±0.008%。细胞免疫荧光(IF)和流式细胞术的体外研究表明,ADSCs-EXO-ICA 可显著抑制 M1 巨噬细胞的增殖。酶联免疫吸附试验、细胞转录组学和实时定量 PCR 表明,ADSCs-EXO-ICA 通过抑制 ERK/HIF-1α/GLUT1 通路抑制糖酵解,促进 M1 向 M2 的表型转化。在体内,ADSCs-EXO-ICA 有效地在关节中积累。药效学评估显示,ADSCs-EXO-ICA 降低了胶原诱导关节炎(CIA)大鼠的细胞因子水平并缓解了关节炎症状。组织学分析和微计算机断层扫描证实,ADSCs-EXO-ICA 显著改善了滑膜炎并保护了软骨。进一步的体内研究表明,ADSCs-EXO-ICA 通过促进 M1 向 M2 的转换和抑制糖酵解来抑制关节炎。Western blot 支持 ADSCs-EXO-ICA 在 RA 中的治疗效果,证实其通过调节能量代谢来调节巨噬细胞功能。因此,本研究不仅介绍了一种药物递送系统,该系统可显著增强 ADSCs-EXO-ICA 的抗 RA 疗效,还阐明了其在抑制巨噬细胞功能中的作用机制。